Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction

PHASE4CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2016

Conditions
Catheter InfectionsEnd-stage Renal Disease
Interventions
DEVICE

4% citrate lock solution regimen

(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).

DEVICE

TauroLock lock solution regimen

After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.

Trial Locations (1)

1180

Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT02789501 - Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction | Biotech Hunter | Biotech Hunter